Medtronic Raises 2027 Forecasts Amid Strong Heart Device Demand
Medtronic anticipates robust growth in 2027 driven by high demand for heart devices and strategic investments.
Medtronic has elevated its fiscal 2027 financial projections, fueled by a surge in demand for its heart devices used in complex cardiovascular procedures. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from its previous estimate of 6.75% to 7.25%. Additionally, the lower end of its adjusted per share profit forecast has been raised to $5.94, up from $5.90, with the upper limit remaining at $6.
Strategic Investments and Growth Prospects
In a move to bolster its heart device portfolio, Medtronic has announced significant investments, including $80 million in Pi-Cardia, a heart-valve repair device maker. This investment includes an option to acquire Pi-Cardia for $210 million. Furthermore, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select international markets. CEO Geoff Martha emphasized the strategic focus on high-growth medical technology segments with substantial patient bases.
Strong Performance Across Business Segments
Medtronic's cardiovascular segment witnessed a 19.5% increase in quarterly sales, reaching $3.93 billion. The growth was primarily driven by its pulsed field ablation portfolio, which saw an impressive 88% rise. This technology is instrumental in treating irregular heart rhythms, contributing significantly to the company’s robust quarterly performance.
In the latest quarter, Medtronic reported an adjusted per share profit of $1.45 on revenues of $9.76 billion, surpassing analyst expectations of $1.39 per share and $9.55 billion in revenue, according to data compiled by LSEG.
Market Dynamics and Future Outlook
Medtronic's Chief Financial Officer Thierry Pieton noted that the company received tariff refunds during the quarter, which nearly offset duties paid. However, these refunds have not been factored into future forecasts. Looking ahead, Medtronic continues to prioritize its growth strategies, focusing on expanding its presence in emerging markets where the penetration of soft tissue robotic surgery remains below 1%.
Overall, Medtronic's strategic investments and robust demand for heart devices position the company favorably for sustained growth, as it continues to expand its offerings and market reach.